Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
FDC ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
FDC Mar-23 |
ADCOCK INGRAM Jun-14 |
FDC/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 318 | 320 | - | |
Low | Rs | 229 | 231 | - | |
Sales per share (Unadj.) | Rs | 107.5 | 95.1 | - | |
Earnings per share (Unadj.) | Rs | 11.7 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 14.0 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 119.5 | 74.6 | - | |
Shares outstanding (eoy) | m | 165.91 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.5 | 2.9 | 87.9% | |
Avg P/E ratio | x | 23.4 | -11.5 | -203.8% | |
P/CF ratio (eoy) | x | 19.5 | -13.9 | -140.7% | |
Price / Book Value ratio | x | 2.3 | 3.7 | 62.1% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 45,368 | 46,446 | 97.7% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 3,909 | 2,915 | 134.1% | |
Avg. sales/employee | Rs Th | 0 | 3,739.2 | - | |
Avg. wages/employee | Rs Th | 0 | 679.0 | - | |
Avg. net profit/employee | Rs Th | 0 | -942.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 17,838 | 16,052 | 111.1% | |
Other income | Rs m | 512 | 112 | 455.8% | |
Total revenues | Rs m | 18,350 | 16,165 | 113.5% | |
Gross profit | Rs m | 2,496 | -2,782 | -89.7% | |
Depreciation | Rs m | 389 | 693 | 56.2% | |
Interest | Rs m | 41 | 435 | 9.4% | |
Profit before tax | Rs m | 2,578 | -3,797 | -67.9% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 640 | 237 | 269.6% | |
Profit after tax | Rs m | 1,938 | -4,045 | -47.9% | |
Gross profit margin | % | 14.0 | -17.3 | -80.7% | |
Effective tax rate | % | 24.8 | -6.2 | -397.1% | |
Net profit margin | % | 10.9 | -25.2 | -43.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 14,431 | 11,757 | 122.7% | |
Current liabilities | Rs m | 7,296 | 6,615 | 110.3% | |
Net working cap to sales | % | 40.0 | 32.0 | 124.9% | |
Current ratio | x | 2.0 | 1.8 | 111.3% | |
Inventory Days | Days | 265 | 111 | 238.9% | |
Debtors Days | Days | 251 | 124 | 202.5% | |
Net fixed assets | Rs m | 17,347 | 6,853 | 253.1% | |
Share capital | Rs m | 166 | 75 | 222.6% | |
Net worth | Rs m | 19,820 | 12,599 | 157.3% | |
Long term debt | Rs m | 6 | 4,428 | 0.1% | |
Total assets | Rs m | 31,796 | 23,801 | 133.6% | |
Interest coverage | x | 64.1 | -7.7 | -828.7% | |
Debt to equity ratio | x | 0 | 0.4 | 0.1% | |
Sales to assets ratio | x | 0.6 | 0.7 | 83.2% | |
Return on assets | % | 6.2 | -15.2 | -41.0% | |
Return on equity | % | 9.8 | -32.1 | -30.5% | |
Return on capital | % | 13.2 | -19.8 | -66.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,549 | 1,370 | 113.1% | |
From Investments | Rs m | 111 | -421 | -26.5% | |
From Financial Activity | Rs m | -1,800 | 4,018 | -44.8% | |
Net Cashflow | Rs m | -138 | 4,968 | -2.8% |
Compare FDC With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare FDC With: J.B.CHEMICALS CORAL LAB. AMBALAL SARABHAI GUJ.INJ(KER) MANKIND PHARMA
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.